Barely Significant
← all excerpts

Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis.

Front Oncol · 2020 · PMC7076172 · PMID 32211312

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

marginally significantP = 0.050actually significant
Colitis Compared with chemotherapy alone, patients who received PD-1 inhibitor plus chemotherapy were associated with marginally significant increased risk of colitis (RR = 2.90, 95% CI, 1.02–8.21, P = 0.050; I 2 = 0%).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.